SlideShare a Scribd company logo
1 of 40
Alexander Gabibov Mechanisms of Antigen degradation Workshop "Biomedical technologies at Skokovo. Opportunities and challenges"
Antigen degradation machinery
A nti B odies Catalytic Antibodies EN zymes ABzymes
Catalytic Antibodies .  Historical Background
Five ways to obtain catalytic antibodies  Immunization by transition state analog of reaction Production of antiidiotypic antibody Reactive immunization Induction of autoimmune disease Screening of phage- display libraries Belogurov et al, BioEssays 2009
Organophosphorous poisons ,[object Object],[object Object],[object Object],[object Object]
9A8 may covalently accept and destroy anti-acetylcholine esterase poisons from blood stream  Kolesnikov et al, PNAS 2000 3D  Structure  of the 9A8 Antiidiotypic Antibody Active Site ,[object Object],[object Object],[object Object]
Soman r9A8 interact with soman-MCA RFU Time, h
Combinatorial approach Rational design High resolution 3D Effective screening Directed evolution
-streptavidin molecule -BSA molecule -Biotin group -Phosphonate group Control well Experimental well Phage pull after reaction with Bt-X phosphonate Nonspecific sorbsion Nonspecific and specific sorbsion Trypsin elution Phage amplification Next rounds of selection Bt-X Reactive (covalent) selection
A.17 Catalytic Antibody Biotin-X-phosphonate Griffin.1 scFv library + Screening for  biotin-X binding Conversion into the full-size human antibody crystal Reshetnyak et al, JACS 2007
A.17 antibody has unusual deep cavity with nucleophilic tyrosine at its base
A.17 antibody has unusual deep cavity with  nucleophilic tyrosine at its base  Comparison of active site cavities of natural and created  de novo  biocatalysts. Chemically selected  reactibody  A.17 possess deepest substrate binding niche.  Cross-section views of the active center of esterolytic antibodies 49G7, TEPC15, aldolase antibody 33F12, choline esterases AChE and BChE and antibody  A.17  complexed with their ligands.
The pre-existing primitive active site of the A.17 antibody stereo-selectively interacts with P(R)-isomer of the phosphonate molecule Tyr59 Tyr53 Tyr33 Tyr34 Trp109 Tyr37 Trp92 Trp48 Phe100 OP compound Tyr 37 OH P(R) Tyr 37 P(S) SN2 Tyr59 Tyr53 Tyr33 Tyr34 Trp109 Asn105 Ala107 Phe100 Trp92 Trp48 Cl - 2.5 Å  3.3 Å 3.2 Å Ser51 2.8 Å  Tyr37
A.17 antibody hydrolyzes organophosphorus pesticide – paraoxon by multi-step covalent catalysis.  Covalent intermediate Amount of released p-nitrophenol in case of the reaction with paraoxon is evidently higher than concentration of active sites The reaction rate increased linearly with hydroxylamine concentration. It allows to define that dephosphorylation is rate limiting step k 2  = 1.1 ± 0.1 x10 -1  min -1 k 3  = 1.6 ± 0.2 x10 -2  min -1 k 4  = 1.26 ± 0.09 x10 -3  min -1 Tyr Tyr + Tyr Tyr Tyr Tyr + +
The reaction mechanism of paraoxon hydrolysis by A.17 antibody proceeds through the phosphotyrosine covalent intermediate.  1578.5 m/z=30 1578.5 m/z=30 1583.0 m/z=30 Δ m=135 ( ) (unmodified Fab A.17) (phosphonylated Fab A.17) (unmodified Fab A.17)
Perspectives: generation of artificial biocatalysts  in vivo
MESSAGE ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],Belogurov et al, BioEssays 2009
CDRH3 DNA Possible  catalytic  residues Schuster et al, Science, 1992, Gololobov et al, PNAS, 1995; Gololobov et al.  Mol Immunol. 1997. Structural Similarity Between BV04-01 and MRL-4 anti-DNA Autoantibodies: DNA-binding and DNA-cleaving Activities are Germline-Encoded
Do Myelin-Directed Antibodies Predict Multiple Sclerosis? N EJM,  2003  The B-Cell – Old Player, New Position on the Team NEJM,  2008 Multiple sclerosis B-cells as one of the key players in the MS Environmental hypothesis of MS induction. EBV virus involvement.
Environmental hypothesis of MS induction. EBV virus involvement.  Antibodies   selected from MS Phage-display library are crossreactive towards both, Myelin Basic Protein and EBV latent membrane protein 1.
Abzymatic Site-specific MBP hydrolysis The cleavage sites are localized inside the encephalitogenic epitopes  MBP Musse  et   al, PNAS 2006 Ponomarenko et al, PNAS 2006
Specific B-Cells depletion in MS Toxin Autoreactive B-Cell B-Cell Receptor (BCR), fragments of myelin basic protein (MBP) BCR MBP CD 4 CD 25High TOLERANCE
C D A B Autoantibody binding pattern
Specific B-Cells depletion in MS Fc-based immunotoxins are shown to be the best in the presented set due to the excellent specific/unspecific cytotoxicity ratio
MDS score versus days post disease induction (surrounding pictures). Peptides were applied at days 7-11 (120 μg/rat per day) after disease induction by nasal route. Maximum clinical score in each group of rats, median and 95% confidential interval (in the middle). NS - not significant Belogurov et. al Autoimmunity Administration of MBP peptides to DA rats with EAE
[object Object],[object Object],[object Object],Clinical trials of MBP46-62 formulation in DA rats
P IP
The level of IP in the brain is dramatically elevated during EAE development in SJL/J mice.
Immunoproteasome localization in mice brain. LMP2 and LMP7 are carried by different cells.
MBP hydrolysis by proteasome and enzymes. LC-ESI approach.
Enhanced release of encephalitogenic peptide by immunoproteasome. LC-ESI approach with isotope labeled peptide.
[object Object],[object Object],[object Object]
Expression of LMP7 immunosubunit is significantly decreased by siRNA administration
Low-weight proteasome inhibitors
Low-weight inhibitors efficiently inhibit immunoproteasome  in vitro  and ameliorate EAE  in vivo
Immunoproteasome as a target for MS treatment
Der Mensch als Industriepalast (Man as Industrial Palace)  Stuttgart, 1926. Chromolithograph. National Library of Medicine.  Fritz Kahn (1888-1968) Kahn’s modernist visualization of the digestive and respiratory system as "industrial palace," really a chemical plant
M.M. Shemyakin & Yu.A. Ovchinnikov Institute of Bioorganic Chemistry,  Russian Academy of Sciences Authors: Alexandre G. Gabibov , Alexey A. Belogurov Jr., Ivan V. Smirnov, Inna N. Kurkova, Ekaterina Kuzina, Alexey Kononikhin,   Alexey Stepanov, Natalie A. Ponomarenko, Andrey V. Reshetnyak
COLLABORATION RUSSIA Prof. Eugene Nikolaev Institute of Biochemical Physics RAS   Prof. Alexey Boyko Moscow MS Center Prof. Dmitry Knorre , Prof. Olga Fedorova, Dr. Nikita Kuznetsov  Dr. Dmitry Genkin Dr. Dobroslav Melamed USA Prof. Al Tramontano ,  UC Davis, Medical school National Institute of Allergy and Infectious Diseases  National Institutes of Health  Dr.   Herbert C. Morse III ; Ciphergen Biosystems, Inc FRANCE Prof. Daniel Thomas, Alain Friboulet, Drs. Dominidue Pillet, Marjorie Paon, Berangere Avalle . The University of Technology, Compiegne Prof. Patrick Masson , Drs  Eugénie Carletti, Florian Nachon Département de Toxicologie – CRSSA Institut de Recherche Biomédicale des Armées

More Related Content

What's hot

What's hot (20)

Abzymes
AbzymesAbzymes
Abzymes
 
Complement fixation
Complement fixationComplement fixation
Complement fixation
 
Antiboy- Structure and Function
Antiboy- Structure and FunctionAntiboy- Structure and Function
Antiboy- Structure and Function
 
Antigen-Antibody Interactions, Immune Assays and Experimental Systems
Antigen-Antibody Interactions, Immune Assays and Experimental SystemsAntigen-Antibody Interactions, Immune Assays and Experimental Systems
Antigen-Antibody Interactions, Immune Assays and Experimental Systems
 
The complement system
The complement systemThe complement system
The complement system
 
Antibody Conjugation
Antibody ConjugationAntibody Conjugation
Antibody Conjugation
 
Antibody conjugation
Antibody conjugation Antibody conjugation
Antibody conjugation
 
Proteome-wide covalent ligand discovery in native biological systems
Proteome-wide covalent ligand discovery in native biological systemsProteome-wide covalent ligand discovery in native biological systems
Proteome-wide covalent ligand discovery in native biological systems
 
Antibody
AntibodyAntibody
Antibody
 
Antigen antibody reactions
Antigen antibody reactionsAntigen antibody reactions
Antigen antibody reactions
 
Lecture 5
Lecture 5Lecture 5
Lecture 5
 
Invaders Of The Body
Invaders Of The  BodyInvaders Of The  Body
Invaders Of The Body
 
Heat shock proteins
Heat shock proteinsHeat shock proteins
Heat shock proteins
 
Complement final
Complement finalComplement final
Complement final
 
Preeti
PreetiPreeti
Preeti
 
Precipitation Reaction
Precipitation ReactionPrecipitation Reaction
Precipitation Reaction
 
Antibody & Complements
Antibody & ComplementsAntibody & Complements
Antibody & Complements
 
Poster ECB 2018 - IBL INSIBIO - CONICET
Poster ECB 2018 - IBL INSIBIO - CONICETPoster ECB 2018 - IBL INSIBIO - CONICET
Poster ECB 2018 - IBL INSIBIO - CONICET
 
Antibodies
AntibodiesAntibodies
Antibodies
 
About Heat shock proteins.
About Heat shock proteins.About Heat shock proteins.
About Heat shock proteins.
 

Similar to Gabibov Alexander mechanisms of antigen degradation

ArrayBridge(2016)
ArrayBridge(2016)ArrayBridge(2016)
ArrayBridge(2016)Xing Wang
 
Antimicrobial Activity Of Human Prion Protein Is Mediated By Its N Terminal R...
Antimicrobial Activity Of Human Prion Protein Is Mediated By Its N Terminal R...Antimicrobial Activity Of Human Prion Protein Is Mediated By Its N Terminal R...
Antimicrobial Activity Of Human Prion Protein Is Mediated By Its N Terminal R...Alfonso Enrique Islas Rodríguez
 
Protein corona associated with nanoparticles
Protein corona associated with nanoparticlesProtein corona associated with nanoparticles
Protein corona associated with nanoparticlesANJUNITHIKURUP
 
Role of Oxidative Stress on male infertility
Role of Oxidative Stress on male infertilityRole of Oxidative Stress on male infertility
Role of Oxidative Stress on male infertilityFavourji
 
polyclonal antibodies
polyclonal antibodiespolyclonal antibodies
polyclonal antibodiesnida rehman
 
Sortase A Inhibition By Ugi Products
Sortase A Inhibition By Ugi ProductsSortase A Inhibition By Ugi Products
Sortase A Inhibition By Ugi Productsdavidabulger
 
Monoclonal antibody, history, development and progress
Monoclonal antibody, history, development and progressMonoclonal antibody, history, development and progress
Monoclonal antibody, history, development and progressRadhika Hegde
 
Omar Quintero Resume early Sept 2016 linkedin
Omar Quintero Resume early Sept 2016 linkedinOmar Quintero Resume early Sept 2016 linkedin
Omar Quintero Resume early Sept 2016 linkedinOmar Quintero-Monzon
 
Expression, purification and spectroscopic characterization of the cytochrome...
Expression, purification and spectroscopic characterization of the cytochrome...Expression, purification and spectroscopic characterization of the cytochrome...
Expression, purification and spectroscopic characterization of the cytochrome...John Clarkson
 
mBio-2015-Melnyk-
mBio-2015-Melnyk-mBio-2015-Melnyk-
mBio-2015-Melnyk-Ryan Melnyk
 
Protein-protein interaction
Protein-protein interactionProtein-protein interaction
Protein-protein interactionsigma-tau
 
Gate life sciences 2009
Gate life sciences 2009Gate life sciences 2009
Gate life sciences 2009Anna Purna
 
Human, Eukaryotic And Vitro Associations Of Murine Sec...
Human, Eukaryotic And Vitro Associations Of Murine Sec...Human, Eukaryotic And Vitro Associations Of Murine Sec...
Human, Eukaryotic And Vitro Associations Of Murine Sec...Rachel Davis
 
OPG ELISA Assay Publication
OPG ELISA Assay PublicationOPG ELISA Assay Publication
OPG ELISA Assay PublicationNihal Sarikaya
 
RecA foscused antibacterial screening
RecA foscused antibacterial screeningRecA foscused antibacterial screening
RecA foscused antibacterial screeningtimwigle
 
Advanced &immunomolecular diagnostic techniques dr.ihsan alsaimary
Advanced &immunomolecular diagnostic techniques dr.ihsan alsaimaryAdvanced &immunomolecular diagnostic techniques dr.ihsan alsaimary
Advanced &immunomolecular diagnostic techniques dr.ihsan alsaimarydr.Ihsan alsaimary
 
Screening of receptor like kinase mutants of Arabidopsis thaliana using prote...
Screening of receptor like kinase mutants of Arabidopsis thaliana using prote...Screening of receptor like kinase mutants of Arabidopsis thaliana using prote...
Screening of receptor like kinase mutants of Arabidopsis thaliana using prote...Thomas Welch
 
Biosensors and Bioelectr
Biosensors and Bioelectr Biosensors and Bioelectr
Biosensors and Bioelectr Charles Zhang
 
Assay Virtual Screening Compounds for the Inhibitory Potencies against BACE 1
Assay Virtual Screening Compounds for the Inhibitory Potencies against BACE 1Assay Virtual Screening Compounds for the Inhibitory Potencies against BACE 1
Assay Virtual Screening Compounds for the Inhibitory Potencies against BACE 1Ben Leong
 

Similar to Gabibov Alexander mechanisms of antigen degradation (20)

ArrayBridge(2016)
ArrayBridge(2016)ArrayBridge(2016)
ArrayBridge(2016)
 
Antimicrobial Activity Of Human Prion Protein Is Mediated By Its N Terminal R...
Antimicrobial Activity Of Human Prion Protein Is Mediated By Its N Terminal R...Antimicrobial Activity Of Human Prion Protein Is Mediated By Its N Terminal R...
Antimicrobial Activity Of Human Prion Protein Is Mediated By Its N Terminal R...
 
Protein corona associated with nanoparticles
Protein corona associated with nanoparticlesProtein corona associated with nanoparticles
Protein corona associated with nanoparticles
 
Role of Oxidative Stress on male infertility
Role of Oxidative Stress on male infertilityRole of Oxidative Stress on male infertility
Role of Oxidative Stress on male infertility
 
Nanobodies
NanobodiesNanobodies
Nanobodies
 
polyclonal antibodies
polyclonal antibodiespolyclonal antibodies
polyclonal antibodies
 
Sortase A Inhibition By Ugi Products
Sortase A Inhibition By Ugi ProductsSortase A Inhibition By Ugi Products
Sortase A Inhibition By Ugi Products
 
Monoclonal antibody, history, development and progress
Monoclonal antibody, history, development and progressMonoclonal antibody, history, development and progress
Monoclonal antibody, history, development and progress
 
Omar Quintero Resume early Sept 2016 linkedin
Omar Quintero Resume early Sept 2016 linkedinOmar Quintero Resume early Sept 2016 linkedin
Omar Quintero Resume early Sept 2016 linkedin
 
Expression, purification and spectroscopic characterization of the cytochrome...
Expression, purification and spectroscopic characterization of the cytochrome...Expression, purification and spectroscopic characterization of the cytochrome...
Expression, purification and spectroscopic characterization of the cytochrome...
 
mBio-2015-Melnyk-
mBio-2015-Melnyk-mBio-2015-Melnyk-
mBio-2015-Melnyk-
 
Protein-protein interaction
Protein-protein interactionProtein-protein interaction
Protein-protein interaction
 
Gate life sciences 2009
Gate life sciences 2009Gate life sciences 2009
Gate life sciences 2009
 
Human, Eukaryotic And Vitro Associations Of Murine Sec...
Human, Eukaryotic And Vitro Associations Of Murine Sec...Human, Eukaryotic And Vitro Associations Of Murine Sec...
Human, Eukaryotic And Vitro Associations Of Murine Sec...
 
OPG ELISA Assay Publication
OPG ELISA Assay PublicationOPG ELISA Assay Publication
OPG ELISA Assay Publication
 
RecA foscused antibacterial screening
RecA foscused antibacterial screeningRecA foscused antibacterial screening
RecA foscused antibacterial screening
 
Advanced &immunomolecular diagnostic techniques dr.ihsan alsaimary
Advanced &immunomolecular diagnostic techniques dr.ihsan alsaimaryAdvanced &immunomolecular diagnostic techniques dr.ihsan alsaimary
Advanced &immunomolecular diagnostic techniques dr.ihsan alsaimary
 
Screening of receptor like kinase mutants of Arabidopsis thaliana using prote...
Screening of receptor like kinase mutants of Arabidopsis thaliana using prote...Screening of receptor like kinase mutants of Arabidopsis thaliana using prote...
Screening of receptor like kinase mutants of Arabidopsis thaliana using prote...
 
Biosensors and Bioelectr
Biosensors and Bioelectr Biosensors and Bioelectr
Biosensors and Bioelectr
 
Assay Virtual Screening Compounds for the Inhibitory Potencies against BACE 1
Assay Virtual Screening Compounds for the Inhibitory Potencies against BACE 1Assay Virtual Screening Compounds for the Inhibitory Potencies against BACE 1
Assay Virtual Screening Compounds for the Inhibitory Potencies against BACE 1
 

More from igorod

Принципы политики инновационного центра «Сколково» в области публичных коммун...
Принципы политики инновационного центра «Сколково» в области публичных коммун...Принципы политики инновационного центра «Сколково» в области публичных коммун...
Принципы политики инновационного центра «Сколково» в области публичных коммун...igorod
 
Проект "Разработка оригинальных лекарственных средств для лечения инфекций ви...
Проект "Разработка оригинальных лекарственных средств для лечения инфекций ви...Проект "Разработка оригинальных лекарственных средств для лечения инфекций ви...
Проект "Разработка оригинальных лекарственных средств для лечения инфекций ви...igorod
 
Клаудмак
КлаудмакКлаудмак
Клаудмакigorod
 
Базелевс Инновации
Базелевс ИнновацииБазелевс Инновации
Базелевс Инновацииigorod
 
Сателлит Инновация
Сателлит ИнновацияСателлит Инновация
Сателлит Инновацияigorod
 
М-Пауэр Ворлд
М-Пауэр ВорлдМ-Пауэр Ворлд
М-Пауэр Ворлдigorod
 
ДАТАДВАНС
ДАТАДВАНСДАТАДВАНС
ДАТАДВАНСigorod
 
Фарма Био
Фарма БиоФарма Био
Фарма Биоigorod
 
Уральский центр биофармацевтических технологий
Уральский центр биофармацевтических технологийУральский центр биофармацевтических технологий
Уральский центр биофармацевтических технологийigorod
 
НьюВак
НьюВакНьюВак
НьюВакigorod
 
Команда энергичных предпринимателей
Команда энергичных предпринимателейКоманда энергичных предпринимателей
Команда энергичных предпринимателейigorod
 
АБИ ИнфоПоиск
АБИ ИнфоПоискАБИ ИнфоПоиск
АБИ ИнфоПоискigorod
 
Инноград Пущино
Инноград ПущиноИнноград Пущино
Инноград Пущиноigorod
 
Технопарк «Сколково»
Технопарк «Сколково»Технопарк «Сколково»
Технопарк «Сколково»igorod
 
Научно-технический Центр тонкопленочных технологий на основе кремния
Научно-технический Центр тонкопленочных технологий на основе кремнияНаучно-технический Центр тонкопленочных технологий на основе кремния
Научно-технический Центр тонкопленочных технологий на основе кремнияigorod
 
CeBIT: Благодарственное письмо В.Ф.Вексельбергу (немецкий)
CeBIT: Благодарственное письмо В.Ф.Вексельбергу (немецкий)CeBIT: Благодарственное письмо В.Ф.Вексельбергу (немецкий)
CeBIT: Благодарственное письмо В.Ф.Вексельбергу (немецкий)igorod
 
CeBIT: Благодарственное письмо В.Ф.Вексельбергу
CeBIT: Благодарственное письмо В.Ф.ВексельбергуCeBIT: Благодарственное письмо В.Ф.Вексельбергу
CeBIT: Благодарственное письмо В.Ф.Вексельбергуigorod
 
Презентация проекта литий-ионных аккумуляторов
Презентация проекта литий-ионных аккумуляторовПрезентация проекта литий-ионных аккумуляторов
Презентация проекта литий-ионных аккумуляторовigorod
 
Меморандум о сотрудничестве между Торговым представительством Российской Феде...
Меморандум о сотрудничестве между Торговым представительством Российской Феде...Меморандум о сотрудничестве между Торговым представительством Российской Феде...
Меморандум о сотрудничестве между Торговым представительством Российской Феде...igorod
 
Технопарк «Сколково»
Технопарк «Сколково»Технопарк «Сколково»
Технопарк «Сколково»igorod
 

More from igorod (20)

Принципы политики инновационного центра «Сколково» в области публичных коммун...
Принципы политики инновационного центра «Сколково» в области публичных коммун...Принципы политики инновационного центра «Сколково» в области публичных коммун...
Принципы политики инновационного центра «Сколково» в области публичных коммун...
 
Проект "Разработка оригинальных лекарственных средств для лечения инфекций ви...
Проект "Разработка оригинальных лекарственных средств для лечения инфекций ви...Проект "Разработка оригинальных лекарственных средств для лечения инфекций ви...
Проект "Разработка оригинальных лекарственных средств для лечения инфекций ви...
 
Клаудмак
КлаудмакКлаудмак
Клаудмак
 
Базелевс Инновации
Базелевс ИнновацииБазелевс Инновации
Базелевс Инновации
 
Сателлит Инновация
Сателлит ИнновацияСателлит Инновация
Сателлит Инновация
 
М-Пауэр Ворлд
М-Пауэр ВорлдМ-Пауэр Ворлд
М-Пауэр Ворлд
 
ДАТАДВАНС
ДАТАДВАНСДАТАДВАНС
ДАТАДВАНС
 
Фарма Био
Фарма БиоФарма Био
Фарма Био
 
Уральский центр биофармацевтических технологий
Уральский центр биофармацевтических технологийУральский центр биофармацевтических технологий
Уральский центр биофармацевтических технологий
 
НьюВак
НьюВакНьюВак
НьюВак
 
Команда энергичных предпринимателей
Команда энергичных предпринимателейКоманда энергичных предпринимателей
Команда энергичных предпринимателей
 
АБИ ИнфоПоиск
АБИ ИнфоПоискАБИ ИнфоПоиск
АБИ ИнфоПоиск
 
Инноград Пущино
Инноград ПущиноИнноград Пущино
Инноград Пущино
 
Технопарк «Сколково»
Технопарк «Сколково»Технопарк «Сколково»
Технопарк «Сколково»
 
Научно-технический Центр тонкопленочных технологий на основе кремния
Научно-технический Центр тонкопленочных технологий на основе кремнияНаучно-технический Центр тонкопленочных технологий на основе кремния
Научно-технический Центр тонкопленочных технологий на основе кремния
 
CeBIT: Благодарственное письмо В.Ф.Вексельбергу (немецкий)
CeBIT: Благодарственное письмо В.Ф.Вексельбергу (немецкий)CeBIT: Благодарственное письмо В.Ф.Вексельбергу (немецкий)
CeBIT: Благодарственное письмо В.Ф.Вексельбергу (немецкий)
 
CeBIT: Благодарственное письмо В.Ф.Вексельбергу
CeBIT: Благодарственное письмо В.Ф.ВексельбергуCeBIT: Благодарственное письмо В.Ф.Вексельбергу
CeBIT: Благодарственное письмо В.Ф.Вексельбергу
 
Презентация проекта литий-ионных аккумуляторов
Презентация проекта литий-ионных аккумуляторовПрезентация проекта литий-ионных аккумуляторов
Презентация проекта литий-ионных аккумуляторов
 
Меморандум о сотрудничестве между Торговым представительством Российской Феде...
Меморандум о сотрудничестве между Торговым представительством Российской Феде...Меморандум о сотрудничестве между Торговым представительством Российской Феде...
Меморандум о сотрудничестве между Торговым представительством Российской Феде...
 
Технопарк «Сколково»
Технопарк «Сколково»Технопарк «Сколково»
Технопарк «Сколково»
 

Gabibov Alexander mechanisms of antigen degradation

  • 1. Alexander Gabibov Mechanisms of Antigen degradation Workshop "Biomedical technologies at Skokovo. Opportunities and challenges"
  • 3. A nti B odies Catalytic Antibodies EN zymes ABzymes
  • 4. Catalytic Antibodies . Historical Background
  • 5. Five ways to obtain catalytic antibodies Immunization by transition state analog of reaction Production of antiidiotypic antibody Reactive immunization Induction of autoimmune disease Screening of phage- display libraries Belogurov et al, BioEssays 2009
  • 6.
  • 7.
  • 8. Soman r9A8 interact with soman-MCA RFU Time, h
  • 9. Combinatorial approach Rational design High resolution 3D Effective screening Directed evolution
  • 10. -streptavidin molecule -BSA molecule -Biotin group -Phosphonate group Control well Experimental well Phage pull after reaction with Bt-X phosphonate Nonspecific sorbsion Nonspecific and specific sorbsion Trypsin elution Phage amplification Next rounds of selection Bt-X Reactive (covalent) selection
  • 11. A.17 Catalytic Antibody Biotin-X-phosphonate Griffin.1 scFv library + Screening for biotin-X binding Conversion into the full-size human antibody crystal Reshetnyak et al, JACS 2007
  • 12. A.17 antibody has unusual deep cavity with nucleophilic tyrosine at its base
  • 13. A.17 antibody has unusual deep cavity with nucleophilic tyrosine at its base Comparison of active site cavities of natural and created de novo biocatalysts. Chemically selected reactibody A.17 possess deepest substrate binding niche. Cross-section views of the active center of esterolytic antibodies 49G7, TEPC15, aldolase antibody 33F12, choline esterases AChE and BChE and antibody A.17 complexed with their ligands.
  • 14. The pre-existing primitive active site of the A.17 antibody stereo-selectively interacts with P(R)-isomer of the phosphonate molecule Tyr59 Tyr53 Tyr33 Tyr34 Trp109 Tyr37 Trp92 Trp48 Phe100 OP compound Tyr 37 OH P(R) Tyr 37 P(S) SN2 Tyr59 Tyr53 Tyr33 Tyr34 Trp109 Asn105 Ala107 Phe100 Trp92 Trp48 Cl - 2.5 Å 3.3 Å 3.2 Å Ser51 2.8 Å Tyr37
  • 15. A.17 antibody hydrolyzes organophosphorus pesticide – paraoxon by multi-step covalent catalysis. Covalent intermediate Amount of released p-nitrophenol in case of the reaction with paraoxon is evidently higher than concentration of active sites The reaction rate increased linearly with hydroxylamine concentration. It allows to define that dephosphorylation is rate limiting step k 2 = 1.1 ± 0.1 x10 -1 min -1 k 3 = 1.6 ± 0.2 x10 -2 min -1 k 4 = 1.26 ± 0.09 x10 -3 min -1 Tyr Tyr + Tyr Tyr Tyr Tyr + +
  • 16. The reaction mechanism of paraoxon hydrolysis by A.17 antibody proceeds through the phosphotyrosine covalent intermediate. 1578.5 m/z=30 1578.5 m/z=30 1583.0 m/z=30 Δ m=135 ( ) (unmodified Fab A.17) (phosphonylated Fab A.17) (unmodified Fab A.17)
  • 17. Perspectives: generation of artificial biocatalysts in vivo
  • 18.
  • 19. CDRH3 DNA Possible catalytic residues Schuster et al, Science, 1992, Gololobov et al, PNAS, 1995; Gololobov et al. Mol Immunol. 1997. Structural Similarity Between BV04-01 and MRL-4 anti-DNA Autoantibodies: DNA-binding and DNA-cleaving Activities are Germline-Encoded
  • 20. Do Myelin-Directed Antibodies Predict Multiple Sclerosis? N EJM, 2003 The B-Cell – Old Player, New Position on the Team NEJM, 2008 Multiple sclerosis B-cells as one of the key players in the MS Environmental hypothesis of MS induction. EBV virus involvement.
  • 21. Environmental hypothesis of MS induction. EBV virus involvement. Antibodies selected from MS Phage-display library are crossreactive towards both, Myelin Basic Protein and EBV latent membrane protein 1.
  • 22. Abzymatic Site-specific MBP hydrolysis The cleavage sites are localized inside the encephalitogenic epitopes MBP Musse et al, PNAS 2006 Ponomarenko et al, PNAS 2006
  • 23. Specific B-Cells depletion in MS Toxin Autoreactive B-Cell B-Cell Receptor (BCR), fragments of myelin basic protein (MBP) BCR MBP CD 4 CD 25High TOLERANCE
  • 24. C D A B Autoantibody binding pattern
  • 25. Specific B-Cells depletion in MS Fc-based immunotoxins are shown to be the best in the presented set due to the excellent specific/unspecific cytotoxicity ratio
  • 26. MDS score versus days post disease induction (surrounding pictures). Peptides were applied at days 7-11 (120 μg/rat per day) after disease induction by nasal route. Maximum clinical score in each group of rats, median and 95% confidential interval (in the middle). NS - not significant Belogurov et. al Autoimmunity Administration of MBP peptides to DA rats with EAE
  • 27.
  • 28. P IP
  • 29. The level of IP in the brain is dramatically elevated during EAE development in SJL/J mice.
  • 30. Immunoproteasome localization in mice brain. LMP2 and LMP7 are carried by different cells.
  • 31. MBP hydrolysis by proteasome and enzymes. LC-ESI approach.
  • 32. Enhanced release of encephalitogenic peptide by immunoproteasome. LC-ESI approach with isotope labeled peptide.
  • 33.
  • 34. Expression of LMP7 immunosubunit is significantly decreased by siRNA administration
  • 36. Low-weight inhibitors efficiently inhibit immunoproteasome in vitro and ameliorate EAE in vivo
  • 37. Immunoproteasome as a target for MS treatment
  • 38. Der Mensch als Industriepalast (Man as Industrial Palace) Stuttgart, 1926. Chromolithograph. National Library of Medicine. Fritz Kahn (1888-1968) Kahn’s modernist visualization of the digestive and respiratory system as "industrial palace," really a chemical plant
  • 39. M.M. Shemyakin & Yu.A. Ovchinnikov Institute of Bioorganic Chemistry, Russian Academy of Sciences Authors: Alexandre G. Gabibov , Alexey A. Belogurov Jr., Ivan V. Smirnov, Inna N. Kurkova, Ekaterina Kuzina, Alexey Kononikhin, Alexey Stepanov, Natalie A. Ponomarenko, Andrey V. Reshetnyak
  • 40. COLLABORATION RUSSIA Prof. Eugene Nikolaev Institute of Biochemical Physics RAS Prof. Alexey Boyko Moscow MS Center Prof. Dmitry Knorre , Prof. Olga Fedorova, Dr. Nikita Kuznetsov Dr. Dmitry Genkin Dr. Dobroslav Melamed USA Prof. Al Tramontano , UC Davis, Medical school National Institute of Allergy and Infectious Diseases National Institutes of Health Dr. Herbert C. Morse III ; Ciphergen Biosystems, Inc FRANCE Prof. Daniel Thomas, Alain Friboulet, Drs. Dominidue Pillet, Marjorie Paon, Berangere Avalle . The University of Technology, Compiegne Prof. Patrick Masson , Drs Eugénie Carletti, Florian Nachon Département de Toxicologie – CRSSA Institut de Recherche Biomédicale des Armées

Editor's Notes

  1. 5
  2. основе действия ФОТ лежит необратимое связывание токсина с ацетилхолинэстеразой, что приводит к накоплению ацетилхолина в холинергических синапсах и коллапсу периферической и центральной нервной системы. Различные данные указывают на роль бутирилхолинэстеразы, в предотвращении холинергического кризиса путем связывания и выведения ФОТ из организма. Поэтому БуХэ представляется преспективным средством андотной профилактики и лечения отравлений ФОТ. На сегодняшний день для получения одной дозы БуХЭ необходимо 400 литров человеческой крови. Существующие системы экспресии БуХэ не являются достаточно эффективными
  3. MS is well-known chronic neurodegenerative disease. Long period of time it was postulated that the main aggressors in MS are autoreactive T-Cells specific to major component of myelin membrane – myelin basic protein. However nowadays there is no doubt that B-cells and autoantibodies also have their own important position in attackers team of neurodegenerative process are thought to be one of the key-players in MS.
  4. При рассеянном склерозе одна из причин демиелинизации – это атака цитотоксических лимфоцитов на олигодендроциты в центральной нервной системе. Нами было показано, что подобная атака может быть связана с презентацией на поверхности олигодендроцитов фрагментов основного белка миелина, генерируемых особым энзиматическим комплексом – иммунопротеасомой. Данный переход в свою очередь связан с переходом протеасома – иммунопротеасома, индуцируемым интерфероном. Ингибирование иммунопротеасомы позволит предотвратить некорректную презентацию и тем самым защитить олигодендроциты от цитотоксических лимфоцитов.